PE20212089A1 - Compuestos utiles en la terapia del vih - Google Patents
Compuestos utiles en la terapia del vihInfo
- Publication number
- PE20212089A1 PE20212089A1 PE2021001461A PE2021001461A PE20212089A1 PE 20212089 A1 PE20212089 A1 PE 20212089A1 PE 2021001461 A PE2021001461 A PE 2021001461A PE 2021001461 A PE2021001461 A PE 2021001461A PE 20212089 A1 PE20212089 A1 PE 20212089A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- compounds
- useful compounds
- compound
- hiv therapy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- -1 [(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxyoxolan-2-yl]methyl cyclohexanecarboxylate Chemical compound 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814316P | 2019-03-06 | 2019-03-06 | |
| PCT/IB2020/051878 WO2020178767A1 (en) | 2019-03-06 | 2020-03-04 | Compounds useful in hiv therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212089A1 true PE20212089A1 (es) | 2021-11-04 |
Family
ID=69845479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001461A PE20212089A1 (es) | 2019-03-06 | 2020-03-04 | Compuestos utiles en la terapia del vih |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US12240853B2 (https=) |
| EP (1) | EP3934760A1 (https=) |
| JP (1) | JP2022525013A (https=) |
| KR (1) | KR20210136052A (https=) |
| CN (1) | CN113811360A (https=) |
| AR (1) | AR118240A1 (https=) |
| AU (1) | AU2020231934B2 (https=) |
| BR (1) | BR112021017604A2 (https=) |
| CA (1) | CA3132112A1 (https=) |
| CL (1) | CL2021002309A1 (https=) |
| CO (1) | CO2021012579A2 (https=) |
| CR (1) | CR20210460A (https=) |
| EA (1) | EA202192433A1 (https=) |
| IL (1) | IL285894A (https=) |
| MA (1) | MA55200A (https=) |
| MX (1) | MX2021010700A (https=) |
| PE (1) | PE20212089A1 (https=) |
| PH (1) | PH12021500034A1 (https=) |
| SG (1) | SG11202109253SA (https=) |
| TW (1) | TW202102233A (https=) |
| WO (1) | WO2020178767A1 (https=) |
| ZA (1) | ZA202106096B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021021717A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| PE20221037A1 (es) | 2019-09-11 | 2022-06-17 | Scripps Research Inst | Profarmacos antivirales y composiciones farmaceuticas de los mismos |
| UY38982A (es) | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
| WO2025068743A1 (en) | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| US11718637B2 (en) * | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| JP2024503755A (ja) * | 2020-12-30 | 2024-01-26 | サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー | ウイルス感染症治療用ヌクレオシド系化合物及びその用途 |
| CN116710465A (zh) | 2021-01-25 | 2023-09-05 | 腾盛博药生物科技有限公司 | 腺苷衍生物和包含其的药物组合物 |
| TW202237146A (zh) * | 2021-01-25 | 2022-10-01 | 美商布里生物科學股份有限公司 | 使用腺苷衍生物及衣殼抑制劑之hiv組合療法 |
| JP2024507550A (ja) * | 2021-02-23 | 2024-02-20 | ヴィーブ、ヘルスケア、カンパニー | Ｈｉｖ療法に有用な化合物 |
| CN120958007A (zh) * | 2023-01-30 | 2025-11-14 | 默沙东有限责任公司 | 4'-取代核苷逆转录酶抑制剂的前药 |
| CN121909019A (zh) | 2023-09-27 | 2026-04-21 | Viiv保健英国第三有限公司 | 药物组合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ATE250623T1 (de) | 1999-05-12 | 2003-10-15 | Yamasa Corp | 4'-c-ethynyl-purin-nukleoside |
| EP1378509A4 (en) | 2001-03-19 | 2009-03-25 | Ono Pharmaceutical Co | DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE |
| US7037718B2 (en) | 2001-10-26 | 2006-05-02 | Cornell Research Foundation, Inc. | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| US9770035B2 (en) | 2011-10-06 | 2017-09-26 | Dow Agrosciences Llc | Nucleic acid molecules that target RPA70 and confer resistance to coleopteran pests |
| AU2013235220C1 (en) | 2011-12-22 | 2019-03-28 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| HK1224229A1 (zh) | 2013-06-26 | 2017-08-18 | Alios Biopharma, Inc. | 取代的核苷，核苷酸及其类似物 |
| EP3055319A4 (en) | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| TN2016000566A1 (en) | 2014-06-24 | 2018-04-04 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| LT3160476T (lt) | 2014-06-24 | 2021-04-12 | Janssen Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme |
| WO2016057866A1 (en) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| WO2016066283A1 (en) * | 2014-10-31 | 2016-05-06 | Sandoz Ag | Improved fluorination process |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN108289931B (zh) * | 2015-09-23 | 2022-10-11 | 默沙东公司 | 4’-取代的核苷逆转录酶抑制剂及其制备 |
| JOP20170038B1 (ar) | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| EP4299133A3 (en) | 2016-06-23 | 2024-03-13 | VIIV Healthcare Company | Compositions and methods for the delivery of therapeutics |
| EP3529254B1 (en) | 2016-11-03 | 2023-02-22 | Laurence I. Wu | Prodrugs of clofarabine |
| US20190185508A1 (en) | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
| WO2019199667A2 (en) | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
| WO2020031131A1 (en) | 2018-08-09 | 2020-02-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| JP2021536444A (ja) | 2018-08-30 | 2021-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Ｈｉｖ療法に有用な化合物 |
| ES2971482T3 (es) | 2019-03-06 | 2024-06-05 | Greentech Global Pte Ltd | Dispersiones líquidas para haluros de acilo |
-
2020
- 2020-03-04 AU AU2020231934A patent/AU2020231934B2/en not_active Ceased
- 2020-03-04 WO PCT/IB2020/051878 patent/WO2020178767A1/en not_active Ceased
- 2020-03-04 CA CA3132112A patent/CA3132112A1/en active Pending
- 2020-03-04 PH PH1/2021/500034A patent/PH12021500034A1/en unknown
- 2020-03-04 BR BR112021017604A patent/BR112021017604A2/pt not_active IP Right Cessation
- 2020-03-04 EP EP20712038.7A patent/EP3934760A1/en active Pending
- 2020-03-04 CR CR20210460A patent/CR20210460A/es unknown
- 2020-03-04 TW TW109107136A patent/TW202102233A/zh unknown
- 2020-03-04 KR KR1020217031465A patent/KR20210136052A/ko not_active Withdrawn
- 2020-03-04 PE PE2021001461A patent/PE20212089A1/es unknown
- 2020-03-04 CN CN202080030422.7A patent/CN113811360A/zh active Pending
- 2020-03-04 EA EA202192433A patent/EA202192433A1/ru unknown
- 2020-03-04 JP JP2021552772A patent/JP2022525013A/ja not_active Ceased
- 2020-03-04 SG SG11202109253SA patent/SG11202109253SA/en unknown
- 2020-03-04 AR ARP200100588A patent/AR118240A1/es not_active Application Discontinuation
- 2020-03-04 MA MA055200A patent/MA55200A/fr unknown
- 2020-03-04 MX MX2021010700A patent/MX2021010700A/es unknown
- 2020-05-04 US US16/865,678 patent/US12240853B2/en active Active
-
2021
- 2021-06-01 US US17/335,145 patent/US20220411425A1/en not_active Abandoned
- 2021-08-24 ZA ZA2021/06096A patent/ZA202106096B/en unknown
- 2021-08-26 IL IL285894A patent/IL285894A/en unknown
- 2021-09-03 CL CL2021002309A patent/CL2021002309A1/es unknown
- 2021-09-24 CO CONC2021/0012579A patent/CO2021012579A2/es unknown
-
2023
- 2023-11-14 US US18/508,355 patent/US20240182473A1/en not_active Abandoned
-
2025
- 2025-02-12 US US19/051,307 patent/US20260035371A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020231934B2 (en) | 2023-04-20 |
| CO2021012579A2 (es) | 2021-10-20 |
| MX2021010700A (es) | 2021-10-01 |
| WO2020178767A1 (en) | 2020-09-10 |
| EP3934760A1 (en) | 2022-01-12 |
| CA3132112A1 (en) | 2020-09-10 |
| AU2020231934A8 (en) | 2022-03-24 |
| AU2020231934A1 (en) | 2021-09-23 |
| US20260035371A1 (en) | 2026-02-05 |
| IL285894A (en) | 2021-10-31 |
| ZA202106096B (en) | 2023-03-29 |
| MA55200A (fr) | 2022-01-12 |
| CR20210460A (es) | 2022-02-03 |
| CN113811360A (zh) | 2021-12-17 |
| EA202192433A1 (ru) | 2021-12-28 |
| KR20210136052A (ko) | 2021-11-16 |
| CL2021002309A1 (es) | 2022-09-20 |
| AR118240A1 (es) | 2021-09-22 |
| US20230174534A1 (en) | 2023-06-08 |
| US12240853B2 (en) | 2025-03-04 |
| US20220411425A1 (en) | 2022-12-29 |
| TW202102233A (zh) | 2021-01-16 |
| US20240182473A1 (en) | 2024-06-06 |
| JP2022525013A (ja) | 2022-05-11 |
| BR112021017604A2 (pt) | 2021-11-16 |
| SG11202109253SA (en) | 2021-09-29 |
| PH12021500034A1 (en) | 2022-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212089A1 (es) | Compuestos utiles en la terapia del vih | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| PE20220569A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos | |
| PE20090365A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
| PE20230106A1 (es) | Compuestos de pirimidina fusionados como moduladores de kcc2 | |
| PE20131377A1 (es) | Triazina-oxadiazoles | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20081375A1 (es) | Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5 | |
| PE20171155A1 (es) | Metodos y compuestos para tratar infecciones virales por paramyxoviridae | |
| PE20121157A1 (es) | Compuestos heterociclicos como inhibidores de proteasas serinas | |
| PE20091843A1 (es) | Inhibidores de catepsina c | |
| PE20110833A1 (es) | Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio | |
| PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20080927A1 (es) | Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk) | |
| AR064735A1 (es) | Agonistas de gpcr y composicion farmaceutica en base al compuesto | |
| PE20120691A1 (es) | Derivados de n1-sulfonil-5-fluoropirimidinona | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| PE20121479A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20090902A1 (es) | Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos | |
| PE20231746A1 (es) | Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos | |
| PE20081783A1 (es) | Nuevas 2-aminooxazolinas como ligandos de taar1 | |
| PE20080197A1 (es) | Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s) | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento |